naftopidil has been researched along with Prostatic Hyperplasia in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.53) | 18.2507 |
| 2000's | 40 (47.06) | 29.6817 |
| 2010's | 38 (44.71) | 24.3611 |
| 2020's | 4 (4.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Deng, X; He, X; Li, B; Liang, X; Shao, B; Sun, X; Xu, F; Xu, J; Yuan, M | 1 |
| Cai, Y; Chen, Z; Huang, B; Huang, J; Li, L; Liu, X; Wu, B; Wu, D; Zhan, H; Zhang, S | 1 |
| Kawakami, Y; Kotake, K; Noritake, Y | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Takai, S | 1 |
| Florent, R; N'Diaye, M; Poulain, L | 1 |
| Chai, Y; Che, X; Cui, Y; Zhang, Y; Zhou, Z | 1 |
| Chung, MS; Lee, SH; Yoon, BI | 1 |
| Chung, JI; Hong, JH; Jung, TY; Kang, TW; Kwak, C; Kwon, SY; Lee, JY; Lee, KS; Seo, SI; Yoo, TK; Yun, SJ | 1 |
| Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B | 1 |
| Gandhi, S; Hwang, EC; Jung, JH | 1 |
| Haga, K; Hirose, T; Ichihara, K; Iwasawa, A; Masumori, N; Miyao, N; Nishimura, M; Sasamura, H; Suzuki, N; Taguchi, K; Yamaguchi, Y | 1 |
| Dahm, P; Gandhi, S; Hwang, EC; Imamura, M; Jung, JH; Kim, MH; Pang, R | 1 |
| Kubono, S; Kuramoto, K; Mizutani, H; Takahashi, H; Tanaka, N; Taneyama, T; Yoshida, M | 1 |
| Miernik, A; Praus, F | 1 |
| Akino, H; Aoki, Y; Hattori, T; Ito, H; Matsuta, Y; Nagase, K; Yokoyama, O | 1 |
| Aoki, Y; Hachiya, T; Saito, T; Takahashi, S; Yamaguchi, K; Yoshikawa, T | 1 |
| Araki, M; Araki, T; Monden, K | 1 |
| Benigni, F; Briganti, A; Capitanio, U; Castiglione, F; Di Trapani, E; Hedlund, P; Montorsi, F; Nini, A; Salonia, A; Villa, L | 1 |
| Adachi, T; Kuratsukuri, K; Nakamura, T; Nakatani, T; Ohmachi, T; Tamada, S; Tanaka, T; Yamaguchi, T; Yamamoto, S; Yoshimura, R | 1 |
| Asai, K; Gotoh, M; Kashiwagi, Y; Kasugai, S; Kato, M; Komatsu, T; Matsukawa, Y; Narita, H; Takai, S; Yamamoto, T | 1 |
| Ashitomi, K; Kadekawa, K; Matayoshi, Y; Mukoyama, H; Nishijima, S; Onaga, T; Sakumoto, M; Shimabukuro, H; Shimabukuro, S; Sugaya, K | 1 |
| Ito, N; Kamiyama, Y; Kanamaru, S; Kawakita, M; Matsumoto, K; Muguruma, K; Shirahase, T; Takahashi, T; Tsukazaki, H; Tsunemori, H; Utsunomiya, N | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Narita, H; Ogawa, T; Takai, S | 1 |
| Cai, Y; Fu, X; Guo, J; Guo, Y; Huang, B; Huang, J; Li, A; Liu, X; Rong, Y; Wu, B; Xiao, Q; Yuan, M; Zhang, X; Zhu, L | 1 |
| Egawa, S; Endo, K; Furuta, A; Naruoka, T; Sugaya, S; Suzuki, Y | 1 |
| Awa, Y; Egoshi, K; Hamano, S; Ichikawa, T; Mori, I; Ohki, T; Okano, T; Ota, S; Sakurayama, Y; Suzuki, H | 1 |
| Oh-oka, H | 2 |
| Fujihara, A; Kamoi, K; Kanazawa, M; Miki, T; Okihara, K; Ukimura, O | 1 |
| Gao, JP; Ge, JP; Gong, J; Ma, HQ; Shang, XJ; Wang, D; Wei, W; Xu, S; Zhang, ZY | 1 |
| Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T | 1 |
| Kojima, Y; Miyake, O; Oda, M; Okuyama, A; Tsujihata, M; Uchida, K; Yoshimura, K | 1 |
| Hayashi, Y; Kiniwa, M; Kohri, K; Kojima, Y; Koshimizu, TA; Oda, N; Sasaki, S; Tsujimoto, G | 1 |
| Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T | 1 |
| Fink, HA; Garimella, PS; Macdonald, R; Wilt, TJ | 1 |
| Honda, S; Iwata, S; Kawachi, Y; Maruyama, O; Noto, K; Sakurai, T; Sugimura, S | 1 |
| Funahashi, Y; Gotoh, M; Hattori, R; Komatsu, T; Matsukawa, Y; Sassa, N | 1 |
| Araki, K; Awa, Y; Egoshi, K; Ichikawa, T; Komiya, A; Mikami, K; Nakatsu, H; Naya, Y; Ohki, T; Onishi, T; Ota, S; Sato, N; Suzuki, H | 1 |
| Iwaki, H; Konishi, T; Narita, M; Okada, Y; Sakano, Y; Soga, H | 1 |
| Kazama, T; Kimura, H; Nozaki, T; Okumura, A; Tsuritani, S | 1 |
| Hanyu, S; Hatano, A; Nishiyama, T; Obara, K; Takahashi, K | 1 |
| Fujii, T; Fukumoto, K; Hara, R; Jo, Y; Miyaji, Y; Nagai, A; Sone, A; Yokoyama, T | 1 |
| Aoki, D; Furukawa, M; Hakariya, T; Hayashi, M; Igawa, T; Kanetake, H; Matsuya, F; Nishimura, N; Nomata, K; Onita, T; Sakai, H; Shida, Y; Shiraishi, K; Shono, T; Takehara, K; Tsurusaki, T; Yogi, Y | 1 |
| Hashimoto, Y; Hatakeyama, S; Kamimura, N; Kawaguchi, T; Koie, T; Kudo, S; Ohyama, C; Takahashi, S; Yoneyama, T; Yoshikawa, K | 1 |
| Baba, S; Fujita, T; Hayakawa, K; Ishiyama, H; Kimura, M; Kitano, M; Kotani, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H | 1 |
| Ichikawa, T; Igarashi, T; Ishii, T; Kambara, Y; Nakamura, K; Naya, Y; Sakamoto, S; Sazuka, T; Yamanishi, T | 1 |
| Kakizaki, H; Numata, A; Osanai, H; Watanabe, M; Yamaguchi, S | 1 |
| Park, WH | 1 |
| Ishizuka, O | 1 |
| Funahashi, Y | 1 |
| Fujisawa, M; Haraguchi, T; Minayoshi, K; Miyake, H; Miyazaki, J; Morishita, S; Shigemura, K; Shirakawa, T; Tanaka, K; Yamada, Y | 1 |
| Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J | 1 |
| Asakura, T; Hashiba, T; Jinza, S; Masuda, M; Masuko, H | 1 |
| Ashitomi, K; Hatano, T; Miyazato, M; Nishijima, S; Ogawa, Y; Sugaya, K | 1 |
| Ju, XB; Su, JT; Wu, HF | 1 |
| Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Iinuma, M; Kudou, T; Ohinata, M; Suzuki, A | 1 |
| Araki, I; Fukuzawa, S; Hashimura, T; Soeda, T; Sugino, Y; Takeuchi, H; Taki, Y | 1 |
| Abe, K; Goto, H; Ikemoto, I; Kishimoto, K; Kiyota, H; Miki, K; Ohishi, Y | 1 |
| Furuhata, A; Hirokawa, M; Hiromoto, Y; Ikeda, A; Kawasaki, C; Masuda, M; Nakayama, K; Satomi, Y; Shiramizu, M | 1 |
| Kamai, T; Sakakibara, R; Tsujii, T; Uchiyama, T; Yamanishi, T; Yasuda, K; Yoshida, K | 1 |
| Kaplan, SA | 1 |
| Gotoh, M; Kamihira, O; Kinukawa, T; Ohshima, S; Ono, Y; Origasa, H | 1 |
| Furuya, R; Furuya, S; Hisasue, S; Itoh, N; Masumori, N; Ogura, H; Tsukamoto, T | 1 |
| Kawamura, T; Kitamura, T; Matsushima, H; Tajima, A; Takahashi, S; Tominaga, T | 1 |
| Andriole, GL; Bullock, TL | 1 |
| Morishima, S; Muramatsu, I; Suzuki, F; Tanaka, T; Yamamoto, H | 1 |
| Kawabe, K | 1 |
| Hayashi, M; Kobayashi, M; Kobayashi, S; Shibata, N; Tadachi, M; Tatemichi, S; Tomiyama, Y; Yamazaki, Y | 1 |
| Deguchi, T; Ishihara, S; Masue, T; Miwa, K; Nishino, Y; Takahashi, Y | 1 |
| Kumon, H; Nasu, Y; Takamoto, H; Watanabe, T; Yokoyama, T | 1 |
| Kobayashi, K; Kobayashi, M; Kobayashi, S; Maezawa, A; Maruyama, I; Shibata, N; Tatemichi, S; Tomiyama, Y; Yamazaki, Y | 1 |
| Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R | 1 |
| Fujita, Y; Inamura, M; Koyama, T; Miyoshi, T; Ohashi, Y; Ohki, K; Okamoto, S; Oshika, T; Sakabe, I; Takahashi, K; Yasuma, T | 1 |
| Hamano, S; Murakami, S; Nakatsu, H; Naoi, M; Sekiyama, K; Suzuki, N; Tanaka, M | 1 |
| Hosokawa, Y; Kishino, T; Momose, H; Ono, T; Oyama, N | 1 |
| Hayase, M; Hayashi, Y; Kohri, K; Kojima, Y; Kubota, Y; Sasaki, S; Shinoura, H; Tsujimoto, G | 2 |
| Abe, K; Egaway, S; Furuta, A; Ikemoto, I; Kishimoto, K; Kiyota, H; Kosugi, S; Shimomura, T; Shirai, H; Suzuki, Y; Takeuchi, H; Torii, S | 1 |
| Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T | 1 |
| Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ | 1 |
| Akimoto, S; Nagashima, K; Shimazaki, J; Tojo, M; Yamanishi, T; Yasuda, K | 1 |
| Ikegaki, I | 1 |
| Arai, G; Hayashi, T; Hyochi, N; Kageyama, Y; Kawakami, S; Kihara, K; Kobayashi, T; Masuda, H; Okuno, T; Saito, K; Sakai, Y; Suzuki, M | 1 |
| Kato, Y; Kawabe, K; Kimura, R; Maruyama, M; Matsumoto, K; Mori, R; Suzuki, M; Yamada, S | 1 |
| Fukaya, Y; Itou, K; Kameoka, H; Kuma, Y; Kumakawa, K; Shiraiwa, Y; Yamaguchi, O; Yamanaka, N; Yokota, T; Yokoyama, J | 1 |
13 review(s) available for naftopidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
Drug Repositioning of the α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Drug Repositioning; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Prostatic Neoplasms | 2020 |
Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis.
Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome | 2021 |
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urological Agents | 2017 |
New alpha blockers to treat male lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Treatment Outcome; Urological Agents | 2018 |
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Benzilates; Drug Combinations; Ethamsylate; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Plant Extracts; Prostatic Hyperplasia; Prostatism; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Urological Agents | 2018 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Tamsulosin; Treatment Outcome; Urological Agents | 2019 |
Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Muscarinic Antagonists; Naphthalenes; Phytotherapy; Piperazines; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic | 2014 |
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin | 2009 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2013 |
Emerging drug therapies for benign prostatic hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Calcitriol; Cell Proliferation; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Indazoles; Male; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Serenoa | 2006 |
[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Amino Acid Sequence; Animals; Cloning, Molecular; Drug Design; Drug Tolerance; Humans; Male; Molecular Sequence Data; Naphthalenes; Piperazines; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Urethral Obstruction | 2006 |
[Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Drug Design; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Naphthalenes; Piperazines; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urethral Obstruction | 2006 |
[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding, Competitive; Dogs; Humans; Male; Naphthalenes; Piperazines; Prazosin; Pressure; Prostate; Prostatic Hyperplasia; Rabbits; Receptors, Adrenergic, alpha-1; Urinary Bladder Neck Obstruction; Urination Disorders | 2000 |
40 trial(s) available for naftopidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Demography; Humans; Hypertension; Male; Middle Aged; Naphthalenes; Patient Compliance; Patient Satisfaction; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2017 |
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Tamsulosin; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases | 2018 |
Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Indoles; Kallikreins; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Sexual Behavior; Therapeutics | 2013 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazosin; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome | 2013 |
Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Multivariate Analysis; Naphthalenes; Nocturia; Piperazines; Prostatic Hyperplasia; Quality of Life; Time Factors; Treatment Outcome; Urodynamics | 2015 |
A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2015 |
[A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Receptors, Adrenergic, alpha-1; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urodynamics | 2017 |
Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Effect of naftopidil on nocturia after failure of tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Nocturia; Piperazines; Prostatic Hyperplasia; Quality of Life; Retreatment; Sulfonamides; Tamsulosin; Treatment Failure | 2008 |
Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urination Disorders | 2008 |
[Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urinary Bladder, Overactive | 2008 |
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urologic Diseases | 2009 |
Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urination Disorders | 2009 |
Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Naphthalenes; Organ Size; Piperazines; Prospective Studies; Prostate; Prostatic Hyperplasia; Treatment Outcome; Ultrasonography | 2011 |
Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Prostatism; Quality of Life; Surveys and Questionnaires | 2010 |
A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Japan; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome; Urination Disorders; Urodynamics | 2010 |
[A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Urination | 2010 |
Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Ejaculation; Erectile Dysfunction; Humans; Indoles; Male; Middle Aged; Naphthalenes; Patient Satisfaction; Piperazines; Prostatic Hyperplasia; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination; Urination Disorders | 2011 |
[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urinary Bladder, Overactive | 2011 |
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Analysis of Variance; Brachytherapy; Humans; Indoles; Iodine Radioisotopes; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Sulfonamides; Tamsulosin | 2011 |
Analysis of energy loss mediated by an alpha-1 blocker in patients with benign prostatic hyperplasia using a virtual urethra processed from an endoscopic video image.
Topics: Adrenergic alpha-Antagonists; Endoscopy; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urethra; Urination; Video Recording | 2012 |
α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urination Disorders | 2013 |
Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
Topics: Adrenergic alpha-Antagonists; Aged; Asian People; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prostate; Prostatic Hyperplasia; Treatment Outcome; Urological Agents | 2013 |
[Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
Topics: Adrenergic alpha-Antagonists; Cross-Over Studies; Humans; Indoles; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urination Disorders | 2012 |
[The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Tablets | 2002 |
[Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Urination Disorders | 2003 |
Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Dizziness; Headache; Humans; Hypotension, Orthostatic; Male; Middle Aged; Naphthalenes; Patient Satisfaction; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders | 2003 |
Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Combinations; Ethamsylate; Humans; Male; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Plant Preparations; Prostatic Hyperplasia; Single-Blind Method; Urodynamics | 2004 |
Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Bias; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Ethamsylate; Humans; Male; Muscle Hypertonia; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Prostatic Hyperplasia; Single-Blind Method; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics | 2005 |
Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Urodynamics | 2005 |
Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2006 |
Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urination Disorders; Urodynamics | 2006 |
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Mandelic Acids; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention; Urodynamics | 2006 |
Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders | 2007 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome | 2007 |
Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Biopsy; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospective Studies; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; RNA, Messenger; Sulfonamides; Tamsulosin; Treatment Outcome | 2008 |
Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Treatment Outcome; Urethral Obstruction; Urine; Urodynamics | 1994 |
[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin | 2002 |
32 other study(ies) available for naftopidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
Synthesis, structure-activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Molecular Docking Simulation; Piperazines; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship | 2015 |
Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia.
Topics: Androgens; Animals; Apoptosis; Dihydrotestosterone; Glucuronosyltransferase; Humans; Hyperplasia; Male; Naphthalenes; Piperazines; Prostate; Prostatic Hyperplasia; Rats; Receptors, Androgen; Uridine Diphosphate | 2022 |
Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan.
Topics: Adrenergic Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cholinergic Antagonists; Delirium; Humans; Japan; Male; Pharmacovigilance; Prostatic Hyperplasia; Tamsulosin | 2023 |
Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Tamsulosin; Treatment Outcome | 2018 |
Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Epidemiological Monitoring; Humans; Indoles; Japan; Male; Middle Aged; Naphthalenes; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Surveys and Questionnaires; Tamsulosin; Treatment Outcome | 2019 |
α
Topics: Adrenergic alpha-Antagonists; Animals; Dinoprostone; Disease Models, Animal; Diterpenes; Female; Humans; Male; Muscle Contraction; Naphthalenes; Piperazines; Prostatic Hyperplasia; Rats; Rats, Wistar; TRPV Cation Channels; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination | 2019 |
Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biogenic Monoamines; Dopamine; Epinephrine; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Norepinephrine; Piperazines; Prostatic Hyperplasia; Quality of Life; Serotonin | 2016 |
Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Female; Glucuronides; Infusions, Intravenous; Intestines; Liver; Male; Mass Spectrometry; Microsomes, Liver; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality Control; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereoisomerism; Tandem Mass Spectrometry; Temperature | 2017 |
[Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Drug Combinations; Ethamsylate; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prostatic Hyperplasia; Quality of Life | 2008 |
Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Compliance; Dose-Response Relationship, Drug; Drug Administration Schedule; Dysuria; Humans; Male; Naphthalenes; Nocturia; Piperazines; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2009 |
[The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urinary Retention | 2009 |
Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Animals; Apoptosis; Cell Division; Cell Line; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostate; Prostatic Hyperplasia; Rats; Receptors, Adrenergic, alpha-1; RNA, Messenger | 2009 |
Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Naphthalenes; Pilot Projects; Piperazines; Prognosis; Prostatic Hyperplasia; Prostatism; Retrospective Studies; Sulfonamides; Tamsulosin; Time Factors | 2010 |
[Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Naphthalenes; Nocturia; Piperazines; Prostatic Hyperplasia; Quality of Life; Sleep Wake Disorders; Treatment Outcome | 2010 |
[Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Benzilates; Cholinergic Antagonists; Drug Resistance; Drug Therapy, Combination; Humans; Male; Middle Aged; Naphthalenes; Nocturia; Piperazines; Prospective Studies; Prostatic Hyperplasia | 2011 |
Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urination Disorders | 2013 |
Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urination Disorders | 2013 |
Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urination Disorders | 2013 |
Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Efferent Pathways; Female; Hypogastric Plexus; Injections, Spinal; Male; Muscle Contraction; Muscle, Smooth; Naphthalenes; Parasympathetic Nervous System; Piperazines; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Spinal Cord; Sulfonamides; Tamsulosin; Urinary Bladder | 2002 |
[Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Urination Disorders; Urodynamics | 2003 |
[Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Circadian Rhythm; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Urination; Urination Disorders | 2004 |
[Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Retrospective Studies; Sexual Dysfunctions, Psychological; Sulfonamides; Tamsulosin | 2005 |
Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Retrospective Studies; Treatment Outcome; Urinary Incontinence; Urodynamics | 2006 |
[Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Hypogastric Plexus; Indoles; Male; Naphthalenes; Piperazines; Pressure; Prostate; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urethra | 2006 |
Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Carotid Artery, Common; Data Interpretation, Statistical; Dogs; Electric Stimulation; Heart Rate; Hypogastric Plexus; In Vitro Techniques; Indoles; Male; Naphthalenes; Norepinephrine; Organ Specificity; Piperazines; Prostate; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urethra; Urethral Obstruction; Urinary Tract | 2006 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Female; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2007 |
[The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Nocturia; Piperazines; Prostatic Hyperplasia; Quality of Life; Urination Disorders; Urodynamics | 2007 |
Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Biopsy; Blotting, Western; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Protein Isoforms; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
[A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Kaplan-Meier Estimate; Male; Naphthalenes; Organ Size; Patient Compliance; Piperazines; Prostatic Hyperplasia; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Failure; Urologic Diseases | 2007 |
Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Binding Sites; Binding, Competitive; Humans; Kinetics; Male; Naphthalenes; Piperazines; Prostate; Prostatic Hyperplasia; Radioligand Assay; Receptors, Adrenergic, alpha | 1992 |
[Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Muscle Contraction; Naphthalenes; Piperazines; Prostate; Prostatic Hyperplasia; Urination Disorders | 1991 |